US Edition
Published • loading... • Updated
Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi
The transfer includes intellectual property rights and leaves product availability and patient support unchanged, with over 22,000 U.S. ALS patients treated.
- On Wednesday, Tanabe Pharma America, Inc. finalized the transfer of its RADICAVA business to Shionogi Inc. , including intellectual property and marketing rights for the amyotrophic lateral sclerosis therapy.
- TPA previously announced this transfer on December 22, 2025, allowing the Jersey City, N.J.-based subsidiary to focus on its late-stage pipeline of investigational treatments for difficult-to-treat diseases.
- Since the U.S. Food and Drug Administration approved the treatment in 2022, over 22,000 people with ALS have used RADICAVA ORS, with TPA President Yasutoshi Kawakami stating the company's 'foremost priority' remains patient continuity.
- No changes to supply chains or patient support services are expected, and all established customer-facing contacts for RADICAVA will continue serving patients and their families seamlessly.
- Parent company Tanabe Pharma Corporation, headquartered in Doshomachi, Osaka, maintains its mission of 'Creating hope for all facing illness' through focus on 'precision medicine' and 'around the pill solutions.
Insights by Ground AI
37 Articles
37 Articles
Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone)
Integration Fully Operational on Day One to Ensure Continuity of Care for the ALS Community With More than 100 Team Members Joining Shionogi from Tanabe Pharma America Acquisition Establishes a Strong Commercial Platform in Rare Disease to Support Future LaunchesOSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; more... The post Shionogi Completes Acquisition of All Ri…
Shionogi Completes Acquisition of All Rights to RADICAVA ...
·Crystal River, United States
Read Full ArticleCoverage Details
Total News Sources37
Leaning Left5Leaning Right5Center14Last UpdatedBias Distribution58% Center
Bias Distribution
- 58% of the sources are Center
58% Center
L 21%
C 58%
R 21%
Factuality
To view factuality data please Upgrade to Premium
